{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:46:06Z","timestamp":1789775166205,"version":"4.0.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tianin Key Medical Discipline","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Scientific Foundation of China","doi-asserted-by":"crossref","award":["82172835"],"award-info":[{"award-number":["82172835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, open-label, single-arm phase II trial enrolled patients with stage II-III breast cancer with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. Eligible patients received tucidinostat plus exemestane, and then breast-conserving surgery (BCS) or modified radical mastectomy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 20 enrolled patients, 3 of them achieved preoperative endocrine prognostic index (PEPI) score of 0. Additionally, complete cell cycle arrest was observed in 7, radiologic objective response rate in 10, and disease control rate in 20 patients, pathological complete response in 1 patient, and 5 patients performed BCS. Ki67 suppression from baseline to surgery was observed in 17 of patients, with the Ki67 change ratio of \u221273.5%. Treatment-emergent adverse event included neutropenia, leukopenia, thrombocytopenia, lymphopenia, hypoalbuminemia, aspartate aminotransferase elevation, glutamyl transpeptidase elevation, anemia, and alanine aminotransferase elevation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>ChiCTR2100046678.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae033","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T11:19:26Z","timestamp":1709983166000},"page":"e763-e770","source":"Crossref","is-referenced-by-count":9,"title":["Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer"],"prefix":"10.1093","volume":"29","author":[{"given":"Hongmeng","family":"Zhao","sequence":"first","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ge","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumian","family":"Jia","sequence":"additional","affiliation":[{"name":"The Department of Breast Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[{"name":"The Department of Breast Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchen","family":"Cao","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-745X","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin 300060 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"2024060305572294000_CIT0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume-title":"CA Cancer J Clin","author":"Sung","year":"2021"},{"key":"2024060305572294000_CIT0002","first-page":"1485","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume-title":"J Clin Oncol","author":"Korde","year":"2021"},{"key":"2024060305572294000_CIT0003","first-page":"164","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume-title":"Lancet","author":"Cortazar","year":"2014"},{"key":"2024060305572294000_CIT0004","first-page":"1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume-title":"JAMA","author":"Berry","year":"2006"},{"key":"2024060305572294000_CIT0005","first-page":"902","article-title":"Neoadjuvant endocrine therapy in breast cancer management: state of the art","volume-title":"Cancers (Basel)","author":"Lerebours","year":"2021"},{"key":"2024060305572294000_CIT0006","first-page":"2538","article-title":"The present and future of neoadjuvant endocrine therapy for breast cancer treatment","volume-title":"Cancers (Basel)","author":"Mart\u00ed","year":"2021"},{"key":"2024060305572294000_CIT0007","first-page":"e2020312","article-title":"Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis","volume-title":"JAMA Netw Open","author":"Li","year":"2020"},{"key":"2024060305572294000_CIT0008","first-page":"917","article-title":"Can CDK4\/6 inhibitors cause fatal lung injury","volume-title":"Expert Rev Anticancer Ther","author":"Jazieh","year":"2019"},{"key":"2024060305572294000_CIT0009","first-page":"673","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume-title":"Nat Rev Drug Discovery","author":"Falkenberg","year":"2014"},{"key":"2024060305572294000_CIT0010","first-page":"630","article-title":"Targeting the cancer epigenome for therapy","volume-title":"Nat Rev Genet","author":"Jones","year":"2016"},{"key":"2024060305572294000_CIT0011","first-page":"3974","article-title":"The effect of vicinal difluorination on the conformation and potency of histone deacetylase inhibitors","volume-title":"Molecules","author":"Ariawan","year":"2021"},{"key":"2024060305572294000_CIT0012","first-page":"806","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume-title":"Lancet Oncol","author":"Jiang","year":"2019"},{"key":"2024060305572294000_CIT0013","first-page":"68","article-title":"Endocrine treatment in breast cancer: cure, resistance and beyond","volume-title":"Cancer Treat Rev","author":"Tryfonidis","year":"2016"},{"key":"2024060305572294000_CIT0014","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume-title":"J Natl Cancer Inst","author":"Therasse","year":"2000"},{"key":"2024060305572294000_CIT0015","first-page":"320","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume-title":"Breast","author":"Ogston","year":"2003"},{"key":"2024060305572294000_CIT0016","first-page":"901","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume-title":"Cancer Chemother Pharmacol","author":"Ning","year":"2012"},{"key":"2024060305572294000_CIT0017","first-page":"e70522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume-title":"PLoS One","author":"Yao","year":"2013"},{"key":"2024060305572294000_CIT0018","first-page":"948","article-title":"Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy","volume-title":"Oncoimmunology","author":"Shen","year":"2012"},{"key":"2024060305572294000_CIT0019","first-page":"339","article-title":"Chidamide reverses epidermal growth factor induced endocrine resistance in estrogen receptor-positive breast cancer","author":"Zhou","year":"2018"},{"key":"2024060305572294000_CIT0020","first-page":"1380","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume-title":"J Natl Cancer Inst","author":"Ellis","year":"2008"},{"key":"2024060305572294000_CIT0021","first-page":"5108","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume-title":"J Clin Oncol","author":"Smith","year":"2005"},{"key":"2024060305572294000_CIT0022","first-page":"2342","article-title":"Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031","volume-title":"J Clin Oncol","author":"Ellis","year":"2011"},{"key":"2024060305572294000_CIT0023","first-page":"4055","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume-title":"Clin Cancer Res","author":"Ma","year":"2017"},{"key":"2024060305572294000_CIT0024","first-page":"566","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer","volume-title":"Clin Cancer Res","author":"Hurvitz","year":"2020"},{"key":"2024060305572294000_CIT0025","first-page":"178","article-title":"Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial","volume-title":"J Clin Oncol","author":"Johnston","year":"2019"},{"key":"2024060305572294000_CIT0026","first-page":"123","article-title":"Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict\u2019s value","volume-title":"Endocr Relat Cancer","author":"Chow","year":"2018"},{"key":"2024060305572294000_CIT0027","first-page":"4414","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume-title":"J Clin Oncol","author":"Symmans","year":"2007"},{"key":"2024060305572294000_CIT0028","first-page":"2334","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume-title":"Ann Oncol","author":"Cottu","year":"2018"},{"key":"2024060305572294000_CIT0029","first-page":"e279","article-title":"Breast cancer in China","volume-title":"Lancet Oncol","author":"Fan","year":"2014"},{"key":"2024060305572294000_CIT0030","first-page":"43","article-title":"A large single-center prospective study to investigate the factors influencing the choice of breast-conserving surgery versus mastectomy in Chinese women with early breast cancer","volume-title":"World J Surg Oncol","author":"Li","year":"2023"},{"key":"2024060305572294000_CIT0031","first-page":"e2331078","article-title":"Clinical features and prognoses of patients with breast cancer who underwent surgery","volume-title":"JAMA Netw Open","author":"Liu","year":"2023"},{"key":"2024060305572294000_CIT0032","first-page":"e1473","article-title":"Current status and factors influencing surgical options for breast cancer in China: a nationwide cross-sectional survey of 110 hospitals","volume-title":"Oncologist","author":"Yang","year":"2020"},{"key":"2024060305572294000_CIT0033","first-page":"389","article-title":"Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer","volume-title":"J Med Screen","author":"Canelo-Aybar","year":"2021"},{"key":"2024060305572294000_CIT0034","first-page":"e95","article-title":"Reduction mammaplasty: an advantageous option for breast conserving surgery in large-breasted patients","volume-title":"Surg Oncol","author":"Hernanz","year":"2010"},{"key":"2024060305572294000_CIT0035","first-page":"189","article-title":"Non-doctoral factors influencing the surgical choice of Chinese patients with breast cancer who were eligible for breast-conserving surgery","volume-title":"World J Surg Oncol","author":"Chen","year":"2019"},{"key":"2024060305572294000_CIT0036","first-page":"1587","article-title":"Role of MRI to assess response to neoadjuvant therapy for breast cancer","volume-title":"J Magn Reson Imaging","author":"Reig","year":"2020"},{"key":"2024060305572294000_CIT0037","first-page":"245","article-title":"Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis","volume-title":"Clin Breast Cancer","author":"Gu","year":"2017"},{"key":"2024060305572294000_CIT0038","first-page":"482","article-title":"Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence","volume-title":"Ann Surg Oncol","author":"Rauch","year":"2016"},{"key":"2024060305572294000_CIT0039","first-page":"609","article-title":"Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors","volume-title":"Cancers (Basel)","author":"Salvatorelli","year":"2020"},{"key":"2024060305572294000_CIT0040","first-page":"3731","article-title":"Contrast-enhanced cone-beam breast-CT (CBBCT): clinical performance compared to mammography and MRI","volume-title":"Eur Radiol","author":"Wienbeck","year":"2018"},{"key":"2024060305572294000_CIT0041","first-page":"48","article-title":"Cone beam breast CT with multiplanar and three dimensional visualization in differentiating breast masses compared with mammography","volume-title":"Eur J Radiol","author":"Zhao","year":"2015"},{"key":"2024060305572294000_CIT0042","first-page":"5773","article-title":"Comparison of background parenchymal enhancement (BPE) on contrast-enhanced cone-beam breast CT (CE-CBBCT) and breast MRI","volume-title":"Eur Radiol","author":"Ma","year":"2022"},{"key":"2024060305572294000_CIT0043","first-page":"1805","article-title":"Accuracy of preoperative contrast-enhanced cone beam breast CT in assessment of residual tumor after neoadjuvant chemotherapy: a comparative study with breast MRI","volume-title":"Acad Radiol","author":"Wang","year":"2023"},{"key":"2024060305572294000_CIT0044","first-page":"391","article-title":"Optimal acquisition time to discriminate between breast cancer subtypes with contrast-enhanced cone-beam CT","volume-title":"Diagn Interv Imaging","author":"Chen","year":"2020"},{"key":"2024060305572294000_CIT0045","first-page":"1477","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume-title":"JAMA Oncol","author":"Spring","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae033\/58038474\/oyae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae033\/58038474\/oyae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:43:28Z","timestamp":1717425808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/6\/e763\/7624817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,9]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae033","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,3,9]]}}}